Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pim J French

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2024
Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort StudyThijs van der Vaart, Maarten M J Wijnenga, Karin van Garderen, et al.
Acta Neuropathologica|October 21, 2017
Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratificationMaarten M J Wijnenga, Hendrikus J Dubbink, Pim J French, et al.
Journal of Neuro-Oncology|April 13, 2017
Does early resection of presumed low-grade glioma improve survival? A clinical perspectiveMaarten M J Wijnenga, Tariq Mattni, Pim J French, et al.
Data in Brief|June 23, 2021
The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with gliomaSebastian R van der Voort, Fatih Incekara, Maarten M J Wijnenga, et al.
Neuro-Oncology Advances|July 13, 2023
Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated <i>TERT</i> promoter mutationMaarten M J Wijnenga, Sybren L N Maas, Vera van Dis, et al.
Neuro-Oncology|December 26, 2022
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033Johan M Kros, Elisabeth Rushing, Aimé L Uwimana, et al.
Neuro-Oncology|May 25, 2019
Defining EGFR amplification status for clinical trial inclusionPim J French, Marica Eoli, Juan Manuel Sepulveda, et al.
Neuro-Oncology Advances|October 1, 2021
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell culturesCassandra Verheul, Ioannis Ntafoulis, Trisha V Kers, et al.
Neuro-Oncology|January 4, 2026
Epigenetic evolution of IDHwt glioblastomasBo Deng, Rania Head, Kaspar Draaisma, et al.
Nature Communications|March 14, 2018
TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein AAlex Pines, Madelon Dijk, Matthew Makowski, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2024
Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort StudyThijs van der Vaart, Maarten M J Wijnenga, Karin van Garderen, et al.
Acta Neuropathologica|October 21, 2017
Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratificationMaarten M J Wijnenga, Hendrikus J Dubbink, Pim J French, et al.
Journal of Neuro-Oncology|April 13, 2017
Does early resection of presumed low-grade glioma improve survival? A clinical perspectiveMaarten M J Wijnenga, Tariq Mattni, Pim J French, et al.
Data in Brief|June 23, 2021
The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with gliomaSebastian R van der Voort, Fatih Incekara, Maarten M J Wijnenga, et al.
Neuro-Oncology Advances|July 13, 2023
Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated <i>TERT</i> promoter mutationMaarten M J Wijnenga, Sybren L N Maas, Vera van Dis, et al.
Neuro-Oncology|December 26, 2022
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033Johan M Kros, Elisabeth Rushing, Aimé L Uwimana, et al.
Neuro-Oncology|May 25, 2019
Defining EGFR amplification status for clinical trial inclusionPim J French, Marica Eoli, Juan Manuel Sepulveda, et al.
Neuro-Oncology Advances|October 1, 2021
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell culturesCassandra Verheul, Ioannis Ntafoulis, Trisha V Kers, et al.
Neuro-Oncology|January 4, 2026
Epigenetic evolution of IDHwt glioblastomasBo Deng, Rania Head, Kaspar Draaisma, et al.
Nature Communications|March 14, 2018
TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein AAlex Pines, Madelon Dijk, Matthew Makowski, et al.
Pageof 13